Cambridge, USA-base immuno-oncology company DEM BioPharma has appointment of Nenad Grmusa as chief executive and Christophe Quéva, as chief scientific officer. 27 September 2022
Belgium’s NeuVasQ Biotechnologies, a Université Libre de Bruxelles (ULB) spin-off developing pharmaceuticals to restore blood-brain barrier function, has named Emmanuel Lacroix chief executive and company director. 20 September 2022
ViroCell Biologics, a UK contract development and manufacturing organization (CDMO), has announced the appointment of Susan Nichols to its senior management team as chief business officer (CBO). 20 September 2022
Privately-held US CAR-T company ImmPACT Bio has tasked Jonathan Benjamin with leading its clinical development strategy as the company’s chief medical officer. 14 September 2022
French biotech GenSight Biologics, which is developing gene therapy for rare and neurodegenerative diseases of the eye, is adding to its management team in anticipation of the European commercialization of Lumevoq (lenadogene nolparvovec). 13 September 2022
US biotech Vertex Pharmaceuticals today announced that Jonathan Biller has been appointed chief legal officer, effective September 19, 2022. 8 September 2022
STORM Therapeutics, a UK biotech discovering and developing small molecule therapies targeting RNA modification enzymes for oncology and other diseases, has announced the appointment of Gerald McMahon as president, chief executive and board director. 7 September 2022
Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC). 6 September 2022
Ocugen, a US biotech focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, has announced the appointment of Robert Hopkins as chief medical officer (CMO) and Arun Upadhyay as chief scientific officer (CSO). 1 September 2022
Scandion Oncology, a Danish biotech developing medicines for treatment-resistant cancer, has announced that president and chief executive Bo Rode Hansen will leave his position with immediate effect by mutual agreement. 31 August 2022
Celsius Therapeutics, a privately-held biotech developing precision medicines for cancer and autoimmune disease through single-cell RNA sequencing, has named Sarah Grant its chief medical officer (CMO). 26 August 2022
British biotech Mereo BioPharma has revealed its largest shareholder is agitating to purge certain board members as part of a plan to change the firm’s strategic direction. 23 August 2022
Singapore-based Tessa Therapeutics, a Temasek-backed clinical stage biotech company, today announced the appointment of Thomas Willemsen as its president and chief executive, effective October 1, 2022. 22 August 2022
PsiOxus, a clinical-stage biotechnology company developing a novel platform technology for the targeted delivery of therapeutic transgenes to solid tumors, has announced the appointment of its new chief executive, Howard Davis. 12 August 2022
California, USA-based Appia Bio, a pre-clinical-stage biotechnology company today announced that Jason Damiano has been appointed as its chief scientific officer. 10 August 2022
US discoverer of precision medicines for cancer and other diseases, Flare Therapeutics, today announced the appointment of Amit Rakhit as president and chief executive. 25 July 2022
Versanis Bio, a privately-held biotech advancing novel therapeutics for cardiometabolic diseases, has announced the appointment of Mark Pruzanski as chairman and chief executive 20 July 2022
USA-based Tiziana Life Sciences has moved fast to strengthen its management team following this week’s announcement of the resignation of Kunwar Shailubhai as chief executive, chief scientific officer and board director, effective as of August 1. 19 July 2022
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024